Under the two Drake’s and Lynch’s products, the price of deleterious mutations is what drives mutation costs down (Drake 1991; Lynch 2010; Sung et al. 2012). thus, beneath both of those models, a rise in the common expense of mutations would result in a lower in mutation costs. to look at this, Drak